Fulcrum Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Fulcrum Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-1.8%
Buyback Yield
| Total Shareholder Yield | -1.8% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Sep 13Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Sep 12Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if FULC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FULC's dividend payments have been increasing.
Dividend Yield vs Market
| Fulcrum Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (FULC) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (FULC) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate FULC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FULC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FULC's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FULC has not reported any payouts.